NEOLEUKIN THERAPEUTICS INC

Neoleukin Therapeutics, Inc. (https://www.neoleukin.com/) is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company uses computational methods to design proteins that demonstrate specific pharmaceutical properties. Its primary areas of focus are oncology, inflammation and autoimmunity. Its technology, Neoleukin platform, uses a set of advanced computational algorithms and methods to design functional de novo proteins. Neoleukin’s lead program, NL-201, is a computationally designed de novo protein therapeutic. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities. NL-201 has also shown promise in combination with allogenic cell therapy to expand and maintain populations of transplanted CAR-T and NK cells.

• NEOLEUKIN THERAPEUTICS INC